rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Ginkgo Bioworks Holdings, Inc.

DNA · NYSE

Health CareBiotechnologyJust started movingSynthetic Biology / TechBio

DNA stood above a rising 150-day average in 5 of the last 52 weekly readings, including each of the last 2 weeks. It is 21.8% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Just started moving
Weeks in an uptrend
2 in a row
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$7.3M
Officials’ trades on record
0
Institutions holding
175 (+11)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 5 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$6.8M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months18
Buyers · sellers0 · 5
WhoDidSharesTraded
Steven P. CoenSee remarkssold2,403at $15.005 Oct 2026filed 7 Oct 2026
Christian O. HenryDirectorsold5,000at $7.0815 Sep 2026filed 16 Sep 2026
Steven P. CoenSee remarkssold330at $6.9824 Aug 2026filed 25 Aug 2026
Steven P. CoenSee remarkssold752at $7.9017 Jul 2026filed 20 Jul 2026
Steven P. CoenSee remarkssold307at $8.3322 May 2026filed 26 May 2026
Steven P. CoenSee remarkssold324at $7.9517 Apr 2026filed 20 Apr 2026
Steven P. CoenSee remarkssold33,171at $6.4113 Apr 2026filed 14 Apr 2026
Reshma P. ShettySee remarkssold124,727at $6.4310 Apr 2026filed 13 Apr 2026
Barry Canton10% ownersold124,727at $6.4310 Apr 2026filed 13 Apr 2026
Jason R. KellySee remarkssold109,767at $6.409 Apr 2026filed 10 Apr 2026
Barry Canton10% ownersold13,116at $6.409 Apr 2026filed 10 Apr 2026
Reshma P. ShettySee remarkssold13,116at $6.409 Apr 2026filed 10 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders175+11 on the quarter
New · exited31 · 21
Reported value$358.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20264,282,903$42.4M+640,556+17.6%
VIKING GLOBAL INVESTORS LPunchanged · filed 14 Aug 20263,577,128$35.4M00.0%
Erste Asset Management GmbHadded · filed 28 Jul 20262,536,939$25.9M+589,211+30.3%
BAILLIE GIFFORD & COunchanged · filed 6 Aug 20262,391,649$23.7M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20262,087,293$20.7M+172,865+9.0%
Anchorage Capital Group, L.L.C.unchanged · filed 14 Aug 20261,746,363$17.3M00.0%
Legal & General Group Plcadded · filed 14 Aug 20261,669,419$16.5M+7,832+0.5%
STATE STREET CORPadded · filed 7 Aug 20261,472,370$14.6M+125,711+9.3%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,222,016$12.1M+212,654+21.1%
FORBES J M & CO LLPreduced · filed 20 Jul 2026999,911$9.9M-28,480−2.8%
30 Jun 2024 – 30 Jun 2026
889169Jun 24Dec 24Jun 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Steven P. Coen Company insiderSee remarks · last 5 Oct 20260 · 26
Christian O. Henry Company insiderDirector · last 15 Sep 20260 · 18
Barry Canton Company insider10% owner · last 28 Jul 20260 · 167
Jason R. Kelly Company insiderSee remarks · last 28 Jul 20260 · 168
Reshma P. Shetty Company insiderSee remarks · last 28 Jul 20260 · 167
Harry Sloan Company insiderDirector · last 11 Jun 20262 · 0
Ross Fubini Company insiderDirector · last 11 Jun 20260 · 0
Sri Kosuri Company insiderDirector · last 11 Jun 20260 · 0
Shyam Sankar Company insiderDirector · last 12 Jun 20252 · 0
Kathy Hopinkah Hannan Company insiderDirector · last 11 Jun 20250 · 0
Myrtle S. Potter Company insiderDirector · last 11 Jun 20250 · 0
Mark E. Dmytruk Company insiderSee remarks · last 21 May 20250 · 36

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-185%
Free cash flow marginFY 2025 · to 31 Dec 2025-105%
Return on capital employedFY 2025 · to 31 Dec 2025-30.8%
Research spendFY 2025 · to 31 Dec 2025143%
Revenue growthFY 2025 · to 31 Dec 2025-25.1%
Share count trendFY 2025 · to 31 Dec 20257.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$167.2M
Free cash flowFY 2025 · to 31 Dec 2025−$178.7M

Analyst forecasts

No analyst forecasts yet.